Peptides for healing and injury recovery
Compounds used for injury, tendon, joint, and gut repair.
This group is where the gap between how confident people sound and what has actually been tested is widest. BPC-157 and TB-500 are discussed as if the dosing were worked out, and neither has completed a published human trial. The tendon and gut results everyone quotes came from rats.
That does not make the compounds useless, but it does change what a dose means. Every protocol circulating online was reverse-engineered from animal work by converting milligrams per kilogram, which is not how drug dosing translates between species. Nobody has established a therapeutic range in a person.
The members with real clinical histories were approved for something other than injury repair. Teriparatide, abaloparatide and calcitonin treat osteoporosis, teduglutide treats short bowel syndrome, pentosan is prescribed for bladder pain, and Cerebrolysin is used after stroke in several countries outside the United States. Their pages give the detail. The rest are research chemicals with an enthusiastic user base and thin paperwork.
A 15-amino-acid chain based on a stomach protein, used after injuries. Almost all the evidence is from animals.
A fragment of the repair protein thymosin beta-4, used for muscle and tendon healing. Most evidence is from animals.
The three-amino-acid tail of the hormone alpha-MSH, sold to calm gut and skin without tanning. No human trials exist.
The two most popular healing peptides in one vial. 'Wolverine' is a community nickname, and ratios vary by vendor.
Three peptides in one vial: GHK-Cu for skin, plus BPC-157 and TB-500 for tissue repair.
The GLOW blend (GHK-Cu, BPC-157, TB-500) with KPV added for anti-inflammatory effect.
Carved from EPO to keep its repair signal without thickening the blood. Reached human trials for nerve pain.
A natural signal that relaxes airways and calms the immune system. Used as a nasal spray, and can lower blood pressure.
A 3-amino-acid Khavinson peptide sold for cartilage and joints, with very little human research.
A short Khavinson peptide based on a brain-tissue peptide, taken for nerve recovery on very little human research.
A 4-amino-acid Khavinson peptide sold for liver support, with very little human research.
A short Khavinson peptide sold for liver and digestive support, with very little human research.
A mix of small peptides from pig brain tissue, with the strongest human evidence in its group for stroke and dementia.
A vendor name for TB-500, BPC-157 and KPV in one vial. It sits one component short of KLOW.
A 3-amino-acid Khavinson peptide sold for lung and gut-lining support, with very little human research.
BPC-157, TB-500 and Cartalax in one vial, typically 10 mg of each. Sold as Regeno and as Deadpool. The third is aimed at cartilage.
A very new arginate-salt cousin of BPC-157, aimed at the same repair job with more stability.
A single-chain piece of the hormone relaxin, built to keep its anti-scarring activity and be simpler to make.
A generic name for pig-brain peptide mixtures used in hospitals in India and China. A vendor's vial is none of those.
A 2-amino-acid Khavinson peptide sold for bladder lining support, with very little human research.
The first four residues of TB-500, and something the body already makes. Its anti-scarring effects are in animal models.
Tightens the junctions between gut-lining cells. Studied mainly for celiac disease, and not absorbed into the body.
The working part of parathyroid hormone. It builds new bone, where most osteoporosis drugs only slow the loss.
A 23-residue piece of thrombin sold for fracture and wound healing. Its 503-patient phase 3 failed, and every human dose was micrograms, given locally.
The only approved GLP-2 drug, for people with too little intestine. Not the 'GLP-2' sellers use to mean tirzepatide.
Builds new bone the way teriparatide does, from a different parent hormone. Approved for osteoporosis.
A once-weekly GLP-2 injection for short bowel syndrome whose phase 3 met its main goal, though the FDA wants a second trial, now recruiting.
A 58-residue cow protein that cuts bleeding in heart surgery. Pulled worldwide in 2007 over a mortality signal, then reinstated in Europe after regulators judged that study unreliable.
A 20-residue thrombin blocker modeled on the leech anticoagulant hirudin, given by drip during angioplasty and stenting.
Lowers blood calcium and slows bone breakdown. Approved for osteoporosis, and the least effective drug in that space.
A once-weekly parathyroid hormone for people whose parathyroid glands do not work, now in a phase 3; the approved options are daily.
A Khavinson bioregulator drawn from nerve tissue, sold for brain and nerve support on very little human research.
An experimental five-amino-acid mimic of apolipoprotein E, given by drip in the hospital after brain bleeds and around surgery; no trial has yet shown benefit.
A cyclic peptide that stops platelets clumping, given by drip during heart attacks and stent procedures. Designed from a rattlesnake venom protein.
A twice-weekly GLP-2 injection from Zealand Pharma for short bowel syndrome, recommended for EU approval in September 2026; the FDA wants another trial.
An investigational eye drop made from a 19-residue fragment of lacritin, a natural tear protein, now in phase 2 for neurotrophic keratitis.
An FDA-approved capsule peptide that stays in the gut and draws water into the bowel to treat constipation.
A stroke neuroprotectant that missed its main goal in three large trials; a case study in subgroup findings that did not survive retesting.
An experimental injected peptide for the lung scarring of idiopathic pulmonary fibrosis, tested so far only in healthy volunteers and in mice.
A daily parathyroid hormone replacement for adults with hypoparathyroidism, built as a prodrug that slowly releases teriparatide; FDA-approved in August 2024.
Acts like the natural lubricant in joints and the bladder lining. Used for arthritis and painful bladder.
A seven-residue cyclic MC1R peptide in a capsule that releases in the colon. Its ulcerative colitis trial stopped at 12 patients, and the company reported a p-value from a study it called underpowered.
A melanocortin eye drop for dry eye. Its 575-patient phase 3 missed both co-primary endpoints as planned, and hit one only after the analysis was adjusted for age and sex.
Linaclotide's rival: a copy of the gut hormone uroguanylin with one change, approved for chronic constipation and IBS with constipation.
Shionogi's IV fragment of the HMGB1 protein, meant to call the body's own stem cells to damaged tissue.
A cattle retina extract developed in Russia and used in eye clinics there, from the same family as Cortexin.
A Khavinson bioregulator drawn from cartilage, sold for bone and joint health on very little human research.
A stroke drug approved only in India: a 14-residue fragment of endothelin-1 that switches on the B receptor, now in a US phase 3.
A relative of the protein TB-500 comes from. Sold for repair, though the published work is on prostate tumor spread.
Both are sold for tendon and muscle repair. BPC-157's human trials were enemas for ulcerative colitis, and TB-500's trials did not even use TB-500.
BPC-157's Phase 2 results were never published. KPV has no human trial; neither was tested as an injection for the uses it is sold for.
These are not two products. One contains the other: KLOW is GLOW plus KPV, and neither blend has ever been tested as a blend.
Common questions
Is there human evidence for healing peptides?
Very little. Most of the well-known repair peptides have only animal and cell studies behind them. That does not mean they do nothing, but it does mean no dose has been validated in people.
What is the difference between BPC-157 and TB-500?
BPC-157 is a gastric peptide fragment studied mostly for gut and tendon models; TB-500 is a fragment of thymosin beta-4 studied for cell migration and tissue repair. They are often stacked, but neither has human trial support.
Can you buy healing peptides legally?
They are generally sold as research chemicals, not medicines. Selling them for human use is not legal in most countries, and purity varies by vendor.